Literature DB >> 29890310

Association of FoxP3 promoter polymorphisms with the risk of Graves' disease in ethnic Kashmiri population.

Faheem Shehjar1, Dil Afroze2, Raiz A Misgar1, Sajad A Malik1, Bashir A Laway3.   

Abstract

Graves' disease is a multifactorial autoimmune disorder of the thyroid gland, with some extra-thyroidal complications like eye and skin abnormalities in some patients. GD is more prevalent in women than men and is the leading cause of hyperthyroidism worldwide. A complex interaction between genetic and environmental factors is the proposed cause which triggers immune system to produce autoantibodies stimulating the TSH receptor, leading to clinical manifestations such as hyperthyroidism, diffuse thyroid enlargement (goiter) and often ophthalmopathy in affected individuals. Various Single nucleotide gene polymorphisms (SNPs) have been associated with the risk of GD development including promoter SNPs in Forkhead Box P3 (FOXP3). FOXP3 is an important regulatory factor for T cell development and differentiation and therefore has a prominent role in suppression of autoimmune reactions which may lead to predisposition of GD. There have been some studies on the association of FOXP3 SNPs with GD, but no such investigation has been carried out in ethnic Kashmiri population. So, we aimed to study a possible association of FOXP3 promoter SNPs (-3279C/A, -2383C/T &amp; -3499 A/G) with GD. Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) was used to genotype 285 individuals (135 GD cases and 150 healthy controls) and the results showed statistically significant differences in genotypic and allelic frequencies of cases and controls for -3279C/A SNP [OR, 3.48; 95% CI (2.05-5.92); P < 0.001] and -2383C/T SNP [OR, 5.62; 95% CI (2.43-13.00); P < 0.001], while no significant association was seen in case of -3499 A/G SNP. We conclude that -3279C/A and -2383C/T SNPs have a highly significant association with the risk of GD development in Kashmiri population.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Forkhead box P3 (FoxP3); Graves' disease; Regulatory T cells; Restriction fragment length polymorphism; Single nucleotide polymorphism

Mesh:

Substances:

Year:  2018        PMID: 29890310     DOI: 10.1016/j.gene.2018.06.023

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  6 in total

1.  Circulating microRNA-144-3p and miR-762 are novel biomarkers of Graves' disease.

Authors:  Qiuming Yao; Xuan Wang; Weiwei He; Zhenyu Song; Bin Wang; Jinan Zhang; Qiu Qin
Journal:  Endocrine       Date:  2019-04-04       Impact factor: 3.633

2.  The Association Between Foxp3 Polymorphisms and Risk of Graves' Disease: A Systematic Review and Meta-Analysis of Observational Studies.

Authors:  Han-Ning Li; Xing-Rui Li; Ya-Ying Du; Zhi-Fang Yang; Zheng-Tao Lv
Journal:  Front Endocrinol (Lausanne)       Date:  2020-06-16       Impact factor: 5.555

3.  Meta-analysis reveals significant association between FOXP3 polymorphisms and susceptibility to Graves' disease.

Authors:  Guiqin Tan; Xin Wang; Guangbing Zheng; Juan Du; Fangyu Zhou; Zhongzhi Liang; Wenwen Wei; Hongsong Yu
Journal:  J Int Med Res       Date:  2021-04       Impact factor: 1.671

4.  Correlation of TSHR and CTLA-4 Single Nucleotide Polymorphisms with Graves Disease.

Authors:  Weihua Sun; Xiaomei Zhang; Jing Wu; Wendi Zhao; Shuangxia Zhao; Minglong Li
Journal:  Int J Genomics       Date:  2019-09-03       Impact factor: 2.326

Review 5.  Genetics, Epigenetics, Cellular Immunology, and Gut Microbiota: Emerging Links With Graves' Disease.

Authors:  Fangyu Zhou; Xin Wang; Lingjun Wang; Xin Sun; Guiqin Tan; Wenwen Wei; Guangbing Zheng; Xiaomin Ma; Dan Tian; Hongsong Yu
Journal:  Front Cell Dev Biol       Date:  2022-01-04

6.  Associations between CD160 polymorphisms and autoimmune thyroid disease: a case-control study.

Authors:  Weiwei He; Jing Zhao; Xuerong Liu; Sheli Li; Kaida Mu; Jing Zhang; Jin-An Zhang
Journal:  BMC Endocr Disord       Date:  2021-07-08       Impact factor: 2.763

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.